Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study

[USA] Cardax, Inc. (“Cardax”) (OTCQB:CDXI) announced today that its astaxanthin consumer health candidates CDX-085 and ASTX-1F demonstrated more than two and one-half times higher oral bioavailability than a leading microalgal astaxanthin product in a head-to-head monkey study. The study was conducted by top-tier contract research organizations and bioavailability was determined by measuring the plasma exposure of astaxanthin over four days following a single dose.

David Watumull, president, CEO and founder of Cardax Phramaceuticals
David Watumull, president, CEO and founder of Cardax Phramaceuticals

“We are pleased to see the superior oral bioavailability of our product candidates in a scientifically rigorous study”

CDX-085 is a patented pure ester of nature-identical astaxanthin and ASTX-1F is a proprietary formulation of nature-identical astaxanthin. The enhanced bioavailability of CDX-085 and ASTX-1F compared to microalgal astaxanthin should reduce the size/number of capsules or tablets required to achieve equivalent circulating levels of astaxanthin.

Based on these results, the Company now intends to launch ASTX-1F as a first generation dietary supplement earlier in 2016 than previously expected, followed by CDX-085 as a second-generation dietary supplement and then OTC drug.

“We are pleased to see the superior oral bioavailability of our product candidates in a scientifically rigorous study,” said Cardax CEO, David G. Watumull. “CDX-085 and ASTX-1F provide an unmatched combination of bioavailability, purity, intellectual property, and large scale manufacturing advantages.”

 

View original article at: Cardax Product Candidates Demonstrate Superior Bioavailability vs. Microalgal Astaxanthin in Monkey Study

unnamed2

 

 

Leave a Reply